Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021038500 - ESKETAMINE FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY

Publication Number WO/2021/038500
Publication Date 04.03.2021
International Application No. PCT/IB2020/058030
International Filing Date 28.08.2020
IPC
A61K 31/135 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
CPC
A61K 31/135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
A61K 9/0014
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0014Skin, i.e. galenical aspects of topical compositions
A61K 9/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
Applicants
  • JANSSEN PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • CANUSO, Carla M.
  • FU, Dong-Jing
  • IONESCU, Dawn F.
  • LANE, Roseanne
Agents
  • SHIRTZ, Joseph F.
  • WOODROW, Hal B.
Priority Data
62/892,84128.08.2019US
62/897,59309.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ESKETAMINE FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
(FR) ESKÉTAMINE POUR LE TRAITEMENT DE PATIENTS PRÉSENTANT UN TROUBLE DÉPRESSIF MAJEUR, NOTAMMENT LA SUICIDALITÉ
Abstract
(EN)
The disclosure relates to methods for reducing symptoms of major depressive disorder, including suicidality, in a human patient assessed to be at imminent risk for suicide comprising the administration of esketamine in addition to standard of care treatment. In certain embodiments, the methods comprise determining if the patient has previously attempted suicide, and, if so, treating such patient with a standard of care treatment and a therapeutically effective amount of esketamine, whereas patients determined not to have previously attempted suicide are administered standard of care treatment without treating the patient with esketamine.
(FR)
L'invention concerne des méthodes permettant de réduire les symptômes d'un trouble dépressif majeur, notamment la suicidalité, chez un patient humain évalué comme présentant un risque imminent de suicide, consistant à administrer de l'eskétamine en plus d'un traitement de soins standard. Dans certains modes de réalisation, les méthodes consistent à déterminer si le patient a préalablement réalisé une tentative de suicide, et, si tel est le cas, à traiter un tel patient avec un traitement de soins standard et une quantité thérapeutiquement efficace d'eskétamine, alors qu'un traitement de soins standard sans traitement du patient avec de l'eskétamine est administré aux patients déterminés comme n'ayant pas réalisé auparavant de tentative de suicide.
Latest bibliographic data on file with the International Bureau